Exchange: NASDAQ·Updated 07:40 PM EDT
News
all
press releases
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
More News
Here's How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.read more...
Benzinga
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Zacks
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts
(RTTNews) - Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA increased to $736 million from $633 million. Total income and other revenues was $674 million comp...
Nasdaq News: Markets
Royalty Pharma Q2 26 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Royalty Pharma plc (RPRX) will host a conference call at 8:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results...
Nasdaq News: Markets
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Zacks

Advertisement|Remove ads.